Fukada, Ippei http://orcid.org/0000-0001-7272-3708
Ito, Yoshinori
Kondo, Naoto
Ohtani, Shoichiro
Hattori, Masaya
Tokunaga, Eriko
Matsunami, Nobuki
Mashino, Kohjiro
Kosaka, Taijiro
Tanabe, Masahiko
Yotsumoto, Daisuke
Yamanouchi, Kosho
Sawaki, Masataka
Kashiwaba, Masahiro
Kawabata, Hidetaka
Kuroi, Katsumasa
Morita, Satoshi
Ohno, Shinji
Toi, Masakazu
Masuda, Norikazu http://orcid.org/0000-0002-7302-0278
Article History
Received: 29 June 2021
Accepted: 11 September 2021
First Online: 23 September 2021
Declarations
:
: Yoshinori Ito received funding from AstraZeneca, Chugai, Daiichi Sankyo, MSD and Eli Lilly. Shoichiro Ohtani received remuneration from Chugai, Pfizer, AstraZeneca and Eli Lilly. Eriko Tokunaga received remuneration from Eli Lilly, Chugai and AstraZeneca, Consultant/advisory role from Eli Lilly, Chugai and AstraZeneca. Masahiro Kashiwaba received remuneration from Chugai and Eli Lilly. Hidetaka Kawabata received funding from Taiho, Chugai, Novartis and Daiichi Sankyo. Katsumasa Kuroi received remuneration from Kyowa-Kirin, Eisai, and Chugai. Satoshi Morita received remuneration from AstraZeneca, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly, MSD, Pfizer and Taiho. Shinji Ohno received remuneration from AstraZeneca, Eisai, Pfizer, Eli Lilly and Chugai, Funding from Eisai and Taiho. Masakazu Toi received remuneration from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, AFI technologies, Luxonus, Shionogi and GL Science, Consultant/advisory role from BMS, Daiichi-Sankyo, Eli Lilly, Terumo, Luxonus, Bertis, Kyowa-Kirin, Athenex Oncology and Kansai Medical Net, Funding from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG association, Eisai, Daiichi-Sankyo, AstraZeneca, Astelas, Shimadzu, Yakult, Nippon Kayaku, AFI technologies, Luxonus, Shionogi and GL Science. Norikazu Masuda received remuneration from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai and Takeda, Funding from Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli Lilly, Eisai, Sanofi, Nippon Kayaku and Daiichi Sankyo. Ippei Fukada, Naoto Kondo, Masaya Hattori, Nobuki Matsunami, Kohjiro Mashino, Masahiko Tanabe, Taijiro Kosaka, Daisuke Yotsumoto, Kosho Yamanouchi and Masataka Sawaki declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the FDA (ClinicalTrials.gov NCT01401959) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: The authors affirm that human research participants provided informed consent for publication of the images in Figs. InternalRef removed, InternalRef removed, and InternalRef removed.